Braidwell LP Acquires New Shares in Damora Therapeutics, Inc. Common Stock $DMRA

Braidwell LP acquired a new position in shares of Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) in the second quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 1,620,377 shares of the company’s stock, valued at approximately $42,146,000. Damora Therapeutics, Inc. Common Stock comprises 1.6% of Braidwell LP’s holdings, making the stock its 21st biggest position.

Several other large investors have also recently added to or reduced their stakes in the stock. Geode Capital Management LLC bought a new stake in Damora Therapeutics, Inc. Common Stock in the fourth quarter valued at $266,000. Ikarian Capital LLC bought a new position in shares of Damora Therapeutics, Inc. Common Stock during the fourth quarter worth about $6,574,000. Jain Global LLC acquired a new stake in shares of Damora Therapeutics, Inc. Common Stock in the 4th quarter worth about $2,774,000. Remedium Capital Partners LLC acquired a new stake in shares of Damora Therapeutics, Inc. Common Stock in the 4th quarter worth about $2,772,000. Finally, Boothbay Fund Management LLC bought a new stake in Damora Therapeutics, Inc. Common Stock in the 4th quarter valued at about $2,204,000. 14.20% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research analysts have issued reports on the stock. Wedbush boosted their target price on shares of Damora Therapeutics, Inc. Common Stock from $35.00 to $40.00 and gave the company an “outperform” rating in a research note on Thursday, July 30th. HC Wainwright restated a “buy” rating and issued a $45.00 price target on shares of Damora Therapeutics, Inc. Common Stock in a research note on Tuesday, July 21st. TD Cowen raised Damora Therapeutics, Inc. Common Stock to a “strong-buy” rating in a report on Monday, August 24th. Jefferies Financial Group initiated coverage on Damora Therapeutics, Inc. Common Stock in a research report on Monday, July 27th. They set a “buy” rating and a $50.00 price objective for the company. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Damora Therapeutics, Inc. Common Stock in a report on Thursday, June 18th. Three equities research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Damora Therapeutics, Inc. Common Stock presently has a consensus rating of “Buy” and a consensus price target of $44.00.

Damora Therapeutics, Inc. Common Stock Stock Up 0.1%

DMRA stock opened at $28.18 on Thursday. The company has a market capitalization of $1.74 billion, a P/E ratio of -8.36 and a beta of 1.46. The company has a 50-day simple moving average of $29.53 and a 200 day simple moving average of $26.88. Damora Therapeutics, Inc. Common Stock has a fifty-two week low of $2.45 and a fifty-two week high of $38.33.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) last announced its earnings results on Monday, August 10th. The company reported ($0.39) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.06. Equities analysts anticipate that Damora Therapeutics, Inc. Common Stock will post -2.06 EPS for the current year.

Damora Therapeutics, Inc. Common Stock Company Profile

Galecto Inc is a clinical‐stage biotechnology company developing small‐molecule therapies that target key pathways involved in fibrotic and malignant diseases. The company’s research focuses on inhibiting galectin‐3, an extracellular carbohydrate‐binding protein implicated in inflammation, fibrosis and tumor progression, as well as lysyl oxidase‐like 2 (LOXL2), an enzyme that crosslinks collagen and elastin in fibrotic tissue.

Its lead programs include GB0139, an inhaled galectin‐3 inhibitor in Phase II trials for idiopathic pulmonary fibrosis and other fibrosing lung diseases, and GB1211, an oral galectin‐3 inhibitor being evaluated for systemic fibrotic disorders.